Mario Crovetto
Chief Executive Officer chez IKONISYS S.A.
Fortune : 1 043 $ au 31/03/2024
Profil
Mario P.
Crovetto is currently the Chief Executive Officer & Director at Ikonisys SA. He is also a Member-Supervisory Board at Curetis GmbH.
Previously, he served as an Independent Director at OpGen, Inc. from 2020 to 2024.
Prior to that, he was the Chief Financial Officer at Eurand NV from 1999 to 2011 and the CFO & Vice President-Corporate Development at Recordati SpA from 1990 to 1999.
He also served as an Independent Member-Supervisory Board at Curetis NV from 2015 to 2020.
Mr. Crovetto holds a graduate degree from Harvard University and an undergraduate degree from Università Cattolica del Sacro Cuore Campus di Milano.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
OPGEN, INC.
0,01% | 30/06/2023 | 1 500 ( 0,01% ) | 1 043 $ | 31/03/2024 |
Postes actifs de Mario Crovetto
Sociétés | Poste | Début |
---|---|---|
IKONISYS S.A. | Chief Executive Officer | 01/07/2021 |
Curetis GmbH
Curetis GmbH Medical SpecialtiesHealth Technology Curetis GmbH operates as a molecular diagnostics company which focuses on the development and commercialization of products for diagnosing severe infectious diseases. The firm offers diagnostic solutions for hospitals and large-scale laboratories. Its products include Unyvero L4 Lysator, Unyvero C8 Cockpit, Unyvero A50 Analyzer, and Unyvero Application Cartridges. The company was founded by Andreas Boos, Johannes Bacher, Gerd Lüdke, and Anne Thews in August 2007 and is headquartered in Holzgerlingen, Germany. | Director/Board Member | - |
Anciens postes connus de Mario Crovetto
Sociétés | Poste | Fin |
---|---|---|
OPGEN, INC. | Director/Board Member | 25/03/2024 |
CURETIS N.V. | Director/Board Member | 01/04/2020 |
Eurand NV
Eurand NV Pharmaceuticals: MajorHealth Technology Eurand NV develops pharmaceutical and biopharmaceutical products using proprietary drug formulation technologies. The company was founded in 1984 and is headquartered in Amsterdam, the Netherlands. | Director of Finance/CFO | 01/01/2011 |
RECORDATI | Director of Finance/CFO | 01/01/1999 |
Formation de Mario Crovetto
Harvard University | Graduate Degree |
Università Cattolica del Sacro Cuore Campus di Milano | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 3 |
---|---|
OPGEN, INC. | Commercial Services |
RECORDATI | Health Technology |
IKONISYS S.A. | Health Technology |
Entreprise privées | 3 |
---|---|
Eurand NV
Eurand NV Pharmaceuticals: MajorHealth Technology Eurand NV develops pharmaceutical and biopharmaceutical products using proprietary drug formulation technologies. The company was founded in 1984 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
Curetis GmbH
Curetis GmbH Medical SpecialtiesHealth Technology Curetis GmbH operates as a molecular diagnostics company which focuses on the development and commercialization of products for diagnosing severe infectious diseases. The firm offers diagnostic solutions for hospitals and large-scale laboratories. Its products include Unyvero L4 Lysator, Unyvero C8 Cockpit, Unyvero A50 Analyzer, and Unyvero Application Cartridges. The company was founded by Andreas Boos, Johannes Bacher, Gerd Lüdke, and Anne Thews in August 2007 and is headquartered in Holzgerlingen, Germany. | Health Technology |
Curetis NV
Curetis NV Medical/Nursing ServicesHealth Services Curetis NV engages in the manufacture, research and development, and commercialization of molecular microbiology solutions. It offers unyvero platform, which comprsises of the unyvero system with the A50 analyzer at its core, proprietary software, and single-use, application-specific cartridges. The company was founded by Johannes Bacher, Gerd Luedke and Andreas Boos in August 2007 and is headquartered in Holzgerlingen, Germany. | Health Services |